Solid Biosciences Inc. filed 1 current report with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-04-10. Each change below is quoted from the filing and linked to it.
Every change, newest first
Reported
Effective simultaneously with Mr. Ganot's resignation, the Board decreased the number of Class III directors to three, increased the number of Class I directors to three and appointed Mr. Ganot to fill the vacancy in Class I (with a term expiring at the Company's 2028 Annual Meeting of Stockholders).
Find people with the same kind of experience as the senior executive at Solid Biosciences Inc., with the record behind each one.
Find candidates like senior executive at Solid Biosciences Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Solid Biosciences Inc. is in the news or changes leadership.
Get an alert when Solid Biosciences Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Solid Biosciences Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.